Biomarker Consortium To Launch In October
This article was originally published in The Pink Sheet Daily
Executive Summary
The public/private partnership is administered by NIH and includes FDA, CMS, patient efficacy groups and industry.
You may also be interested in...
Biomarkers Consortium To Investigate Lung Cancer, Non-Hodgkins Lymphoma
Public-private biomedical research partnership will also investigate biomarkers in major depressive disorder, diabetes and pre-diabetes.
Biomarkers Consortium To Investigate Lung Cancer, Non-Hodgkins Lymphoma
Public-private biomedical research partnership will also investigate biomarkers in major depressive disorder, diabetes and pre-diabetes.
Critical Path Should Follow GMP Model, FDA’s Woodcock Says
To avoid public pushback, the Critical Path initiative should focus on science, not regulatory overhauls, Woodcock tells DIA.